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Original Research
Venous Thromboembolism Within
Professional American Sport Leagues
Meghan Bishop,* MD, Matthew Astolfi,* MS, Eric Padegimas,* MD, Peter DeLuca,† MD,
and Sommer Hammoud,†‡ MD
Investigation performed at the Rothman Institute, Philadelphia, Pennsylvania, USA
Background: Numerous reports have described players in professional American sports leagues who have been sidelined with a
deep vein thrombosis (DVT) or a pulmonary embolism (PE), but little is known about the clinical implications of these events in
professional athletes.
Purpose: To conduct a retrospective review of injury reports from the National Hockey League (NHL), Major League Baseball
(MLB), the National Basketball Association (NBA), and the National Football League (NFL) to take a closer look at the incidence of
DVT/PE, current treatment approaches, and estimated time to return to play in professional athletes.
Study Design: Descriptive epidemiology study.
Methods: An online search of all team injury and media reports of DVT/PE in NHL, MLB, NBA, and NFL players available for public
record was conducted by use of Google, PubMed, and SPORTDiscus. Searches were conducted using the professional team
name combined with blood clot, pulmonary embolism, and deep vein thrombosis.
Results: A total of 55 venous thromboembolism (VTE) events were identified from 1999 through 2016 (NHL, n ¼ 22; MLB, n ¼ 16;
NFL, n ¼ 12; NBA, n ¼ 5). Nineteen athletes were reported to have an upper extremity DVT, 15 had a lower extremity DVT, 15
had a PE, and 6 had DVT with PE. Six athletes sustained more than 1 VTE. The mean age at time of VTE was 29.3 years (range,
19-42 years). Mean (±SD) time lost from play was 6.7 ± 4.9 months (range, 3 days to career end). Seven athletes did not return to
play. Players with upper extremity DVT had a faster return to play (mean ± SD, 4.3 ± 2.7 months) than those with lower extremity
DVT (5.9 ± 3.8 months), PE (10.8 ± 6.8 months), or DVT with PE (8.2 ± 2.6 months) (F¼ 5.69, P¼ .002). No significant difference was
found regarding time of return to play between sports.
Conclusion: VTE in professional athletes led to an average of 6.7 months lost from play. The majority of athletes were able to return
to play after a period of anticoagulation or surgery. Those with an upper extremity DVT returned to play faster than those with other
types of VTE. Further study is needed to look into modifiable risk factors for these events and to establish treatment and return-to-
play guidelines to ensure the safety of these athletes.
Keywords: venous thromboembolism (VTE); pulmonary embolism (PE); deep vein thrombosis (DVT); professional athlete; elite
athlete; return to play
Venous thromboembolism (VTE) in professional athletes is
a serious condition, often requiring long-term anticoagula-
tion therapy with potential career- or life-threatening rami-
fications. VTE is an umbrella term encompassing upper
extremity deep vein thrombosis (DVT), lower extremityDVT,
and pulmonary embolism (PE). Recently, numerous press
reports have been published pertaining to VTEs in profes-
sional athletes, including members of the National Football
League (NFL),NationalHockeyLeague (NHL),NationalBas-
ketballAssociation (NBA),andMajorLeagueBaseball (MLB).
However, the clinical implications and long-term sequelae of
VTE in professional athletes remain uninvestigated.
The recent surge in case and press reports of VTEs in
elite athletes warrants a thorough investigation into the
causes, sequelae, and associated risk factors. Case
reports have described VTE in seemingly healthy athletic
populations including young competitive rowers, elite
marathoners, mountaineers, and professional athletes.§
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Increased media attention has led to public awareness of
VTE, particularly in athletes. Various potential risk factors
associated with VTE in professional and elite athletes have
been suggested, including increased travel to and from
competitions, repetitive traumatic episodes resulting in
vascular damage, and the high-force, repetitive nature of
athletics.13,14,19,23,31,37,40
Current research into VTEs in athletic populations
explores the pathogenesis and causes of the disease.
Eichner13 categorized and documented cases of travel-
related VTE in elite athletes after flights. Parker et al37
conducted similar work and found that the hemostatic
balance of coagulation and fibrinolysis was altered after
a marathon in a cohort of runners who underwent long
flights prior to their race. Hull and Harris21 postulated
that elite athletes are predisposed to develop Virchow’s
classic triad of hypercoagulability, vascular fluid stasis,
and vascular damage with consequent VTE because of
potentially thrombogenic risk factors associated with
intense cardiovascular exercise. While VTEs represent
serious medical conditions irrespective of profession, they
can be career-ending in professional athletes. After expe-
riencing a VTE, professional or elite athletes may need to
alter their career plans by either retiring prematurely or
missing prolonged periods of game or practice time due to
the need for long-term anticoagulation therapy.
To date, the media-reported rate of VTE, associated risk
factors, typical treatment protocols, and medical outcomes
within professional athletic leagues in the United States
remain undetermined. The purpose of this study was to
describe the incidence of VTE, current treatment
approaches, and estimated time to return to play within
professional athletic leagues (NFL, NHL, NBA, and MLB).
This knowledge may elucidate risk differences in sport and
subtype of VTE and allow assessment of treatment proto-
cols and medical or return-to-play outcomes.
METHODS
A database of all VTEs among male professional athletes
was compiled for the 4 major professional sport leagues in
the United States (NFL, NHL, NBA, and MLB) via an
online search for potential press releases or public informa-
tion regarding VTE and professional athletes. Comprehen-
sive Google, PubMed, and SPORTDiscus searches were
performed with the name of each team and the terms deep
vein thrombosis, pulmonary embolism, and blood clot. All
relevant links were investigated in detail to identify all
athletes who experienced a VTE. Only athletes with a con-
firmatory news report were included in the study.
Additional player information was compiled along with
injury reports, press releases, and news articles pertaining
to the player and the VTE incident. Player age at VTE was
calculated based on date of incident and birthdate. Known
risk factors, such as family history of VTE, previous history
of VTE, and known clotting disorders, were recorded if they
were available. Treatment protocols were determined
based on news reports and press releases from team orga-
nizations. Time lost was calculated based on the difference
between the diagnosis of VTE and next professional game
played. If the VTE was season ending, the date of the first
game played of the next season was used. All career-ending
and fatal VTEs were noted.
Descriptive statistics were performed on all athletes who
were identified in the VTE search. Chi-square analysis was
used to assess any differences in the percentage of athletes
who returned to play based on sport as well as the percent-
age who returned based on location of VTE. Single-factor
analysis of variance (ANOVA) was used to determine
whether there was a difference in the average time it took
for athletes to return to play based on sport and based on
location of VTE. Potential risk factors for VTE were
assessed by multivariable regression analysis. Microsoft
Excel and R (R Foundation for Statistical Computing) were
used for all statistical calculations.
RESULTS
A total of 55 VTEs were identified in online records from
1999 through 2016. Twenty-two events occurred in NHL
players (Table 1), 16 in MLB players (Table 2), 12 in NFL
players (Table 3), and 5 inNBA players6 (Table 4). Nineteen
athletes were reported to have an upper extremity DVT, 15
had a lower extremity DVT, 15 had a PE, and 6 had a DVT
with PE. MLB was found to have a statistically higher num-
ber of athletes sustaining an upper extremity DVT compared
with other professional sports (P< .001). Six athletes (4NHL,
1MLB, 1NBA) sustainedmore than1VTE.AllMLBathletes
who sustained a VTE were pitchers. For NHL players, 9
played offensive positions, 7 played defensive positions, and
2 were goaltenders. For NBA players, 3 were centers and 1
was a forward. For NFL players, 2 were defensive backs,
4 were defensive linemen, and 6 were offensive linemen.
The average age at the time of VTE was 29.3 years
(range, 19-42 years). Average age per sport was NHL
28 years (range, 19-39 years), MLB 29 years (range,
23-42 years), NFL 30 years (range, 25-36 years), and NBA
30 years (range, 29-38 years). No significant difference in
age was found between sports (P ¼ .640), but the average
age of players with upper extremity DVT (26 years) was
significantly lower than that of players with other VTEs
(P ¼ .002). Numerous nationalities were represented
among the sports (14 different countries); American was
the predominant nationality represented in all sports
except hockey, where Canadian was the predominant
nationality (40.9%) (P < .001). No association was found
between team geographic location (East Coast, West Coast,
Midwest, Canada) and risk of VTE (P ¼ .368).
Risk factors for VTE were assessed, including known
clotting disorder, family history of clotting disorder, preced-
ing injury or trauma, status postsurgery, and prior history
of clot. Identifiable risk factors were found in 22 events,
while 33 events had no specific risk factor noted. Ten events
were associated with a known personal or family history of
a clotting disorder, 5 entailed a prior history of clot with no
confirmed diagnosis of clotting disorder, 4 occurred after
recent injury or trauma, and 3 occurred after surgery. Hav-
ing a potential variable that is known to predispose to
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coagulopathy was found to be a risk factor for VTE in ath-
letes (P ¼ .033). All potential risk factors analyzed are
noted in Tables 1 through 4.
The majority of VTEs were treated with pharmacologic
anticoagulation (oral or injectable) (n ¼ 31, 56%), surgery
(n ¼ 8, 15%), or a combination of the two (n ¼ 16, 29%). One
athlete was treated with a calcium channel blocker in addi-
tion to an anticoagulant. Data on length of treatment with
anticoagulation could be found for 18 VTEs: 3 were treated
with pharmacologic anticoagulation for 2 months (all were
TABLE 1
Details of Venous Thromboembolic Events in NHL Playersa
Type of VTE Treatment Risk Factors Identified
Time Missed
From Play, mo
Year of
Event NHL Team
UE DVT Surgery for clot/first rib/neck muscle
removal; anticoagulation therapy
(2 mo)
Noted after upper body
workout
4.67 2012 Boston Bruins
1 wk of IV anticoagulant for clot
dissolution; 3 mo of oral
anticoagulants
Brother (NHL player)
diagnosed with TOS as well
2.97 2013 Calgary Flames (AHL)
Surgery for first rib removal 5.87 2012 Dallas Stars (AHL)
Surgery for first rib removal 3.07 1999 Los Angeles Kings (AHL)
Surgery for first rib/neck muscle
removal
Brother (NHL player)
diagnosed with TOS as well
2.63 2016 New York Islanders
Surgery for first rib removal,
anticoagulation therapy (2 mo)
2.03 2015 Tampa Bay Lightning
Surgery for first rib removal,
anticoagulation therapy (2 mo)
5.73 2016 Tampa Bay Lightning
LE DVT Oral anticoagulants (9 mo) Event after blocked shot 9.50 2012 Calgary Flames
Anticoagulation therapy (3 mo) Pelvic venous scarring from
childhood trauma
3.50 2006b Nashville Predators
IVC filter placement; Lovenox injections
indefinitely; wears extra padding on
torso and compression stockings
while traveling; undergoes monthly
US of legs and abdomen; times
injections based on practice/game
schedule
Hereditary clotting disorder;
history of prior PE 2 years
before; occurred after
revision ACL reconstruction
10.20 2008b Nashville Predators
Anticoagulation therapy (3 mo) 4.60 2012 New Jersey Devils
Anticoagulation therapy (continued
for 3.5 years)
Hereditary clotting disorder CE 1999 New York Islanders
Anticoagulation therapy 8.33 2002 Toronto Maple Leafs
Anticoagulation therapy (3 mo); no
contact for 3 mo; compression
stockings on flights
3.47 2013 Winnipeg Jets
Surgery for clot dissolution,
anticoagulation therapy (4 mo)
Previous history of pelvic
thrombophlebitis
CE 2013b Pittsburgh Penguins
Anticoagulation therapy Protein C deficiency 0.33 2008b Philadelphia Flyers
PE Lovenox injections indefinitely Hereditary clotting disorder,
prior history of DVT
8.63 2011 Colorado Avalanche
Lovenox injections Hereditary clotting disorder;
occurred after ACL
reconstruction surgery
5.13 2006 New York Rangers
DVT and PE Oral anticoagulants (unknown
duration)
Protein C deficiency; event
after a blocked shot
CE 2015 Buffalo Sabres
Lovenox injections and then Xarelto
indefinitely (did not take on game
day)
Protein C deficiency; prior
history of lower extremity
DVT
6.87 2014b Philadelphia Flyers
Lovenox injections indefinitely Prior history DVT/PE 9.07c 2014b Pittsburgh Penguins
Lovenox injections and then oral
anticoagulant (6 mo)
Occurred 1 wk after ACL
reconstruction
5.03 2014b Pittsburgh Penguins
aACL, anterior cruciate ligament; AHL, American Hockey League; CE, career ending; DVT, deep vein thrombosis; IV, intravenous; IVC,
inferior vena cava; LE, lower extremity; NHL, National Hockey League; PE, pulmonary embolism; TOS, thoracic outlet syndrome; UE, upper
extremity; US, ultrasonography; VTE, venous thromboembolism.
bAthlete with recurrent VTE.
cRetired 3 months after return due to continued blood clot concerns.
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TABLE 2
Details of Venous Thromboembolic Events in MLB Playersa
Type of VTE Treatment Risk Factors Identified
Time Missed
From Play, mo
Year of
Event MLB Team
UE DVT Surgical removal of first rib Family history 7.10 2011 Tampa Bay Rays
Anticoagulation therapy, calcium
channel blockers
0.10 2012 Toronto Blue Jays
Surgical removal of first rib,
anticoagulation therapy
5.20 2015 Atlanta Braves
Surgical repair, anticoagulation therapy 7.53 2015 Detroit Tigers
Surgical repair, anticoagulation therapy TOS previously with surgical
removal of rib in 2001
2.83 2007 Detroit Tigers
Surgical removal (angioplasty),
anticoagulation therapy
12.20 2008 Detroit Tigers
Surgical removal of first rib,
anticoagulation therapy (6 mo)
5.83 2013 Minnesota Twins
Surgical removal of rib 3.50 1999 Minnesota Twins
Surgical removal of clot, vein graft 3.73 2006b Pittsburgh Pirates
Surgical removal of clot, anticoagulation
therapy
1.60 2013 Los Angeles Angels
Surgical removal of clots, anticoagulation
therapy
Previous DVT 3.67 2008b Colorado Rockies
LE DVT Anticoagulation therapy 1 wk post ACL, third-degree sprain 10.87 2012 New York Yankees
PE Anticoagulation therapy CE 2011 Boston Red Sox
Anticoagulation therapy (3-6 mo) Regular air travel 29.20 2006 Chicago Cubs
Anticoagulation therapy 7.63 2002 Texas Rangers
DVT and PE Surgical removal of first rib,
anticoagulation therapy
11.90 2004 Colorado Rockies
aACL, anterior cruciate ligament; CE, career ending; DVT, deep vein thrombosis; LE, lower extremity; MLB, Major League Baseball;
PE, pulmonary embolism; TOS, thoracic outlet syndrome; UE, upper extremity; VTE, venous thromboembolism.
bAthlete with recurrent VTE.
TABLE 3
Details of Venous Thromboembolic Events in NFL Playersa
Type of VTE Treatment Risk Factors Identified
Time Missed
From Play, mo
Year of
Event NFL Team
UE DVT Surgical removal of clot 2.00 2001 Detroit Lions
LE DVT Surgical removal of clot Family history of blood clots 8.13 2015 New York Giants
Surgical removal of clot 5.90 2012 New York Giants
Surgical removal of clot, anticoagulation
therapy; career ending; irreversible damage
to tibialis anterior
CE 2015 Minnesota Vikings
PE Anticoagulation therapy Recent large weight loss
(lost 70 lb recently, down
from 410 lb)
CE 2010 Washington Redskins
Anticoagulation therapy 10.37 1999 Seattle Seahawks
Anticoagulation therapy Major trauma Death 2000 Kansas City Chiefs
Anticoagulation therapy (6 mo) 13.13 2004 Baltimore Ravens
Anticoagulation therapy (6 mo) Previous PE/clotting issues CE 2012 Cleveland Browns
Anticoagulation therapy Fell on ball on chest; air
travel 12 h after
13.23 2000 Atlanta Falcons
Anticoagulation therapy Renal disease; potential
medication side effect
10.07 2006 Carolina Panthers
Anticoagulation therapy (Lovenox injections
for 1 wk followed by 6 mo of oral
anticoagulants)
Impact trauma to chest 9.13 2011 New York Giants
aCE, career ending; DVT, deep vein thrombosis; LE, lower extremity; NFL, National Football League; PE, pulmonary embolism; UE, upper
extremity; VTE, venous thromboembolism.
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upper extremity DVTs in association with surgery for first
rib removal), 1 was treated for 4 months, 6 were treated for
3 months, 6 were treated for 6 months, 1 was treated for
9 months, and 1 was treated for 3.5 years (average,
4.3 months of treatment, excluding the athlete treated for
3.5 years). Four NHL players who had recurrent VTEs were
treated with anticoagulants indefinitely (3 received daily
Lovenox [Sanofi Aventis] injections, 1 received Lovenox
and then Xarelto [Janssen Pharmaceuticals] daily), and 1
NBA player with a recurrent VTE was placed on Xarelto for
3 months and then daily aspirin indefinitely. Twenty-four
athletes underwent some form of surgery for treatment of
their VTE. The most common surgical procedure performed
was surgical clot removal with or without first rib removal
for upper extremity DVT associated with thoracic outlet
syndrome, which was performed in all 19 athletes with
upper extremity DVTs. Four other athletes underwent sur-
gery for lower extremity DVT and 1 athlete underwent sur-
gery for PE, which included surgical clot removal in 4
athletes and inferior vena cava filter placement in 1.
The average time lost from play was 6.7 ± 4.9 months
(range, 3 days to career end). Chi-square analysis of the
percentage of athletes who returned to play revealed no
significant difference between sports (MLB 93.8%, NBA
80.0%, NFL 66.7%, and NHL 86.4%; w2 ¼ 3.89, df ¼ 3,
P ¼ .274). The overall return-to-play rate among all sports
was 85.4%. No significant difference was found in time to
return to play between the different sports. NHL players
returned at 5.3 ± 2.8 months compared with MLB (7.5 ± 7.0
months), NBA (5.3 ± 4.7 months), and NFL (9.0 ± 3.7
months) (F ¼ 1.36, P ¼ .268). Location of the VTE did not
have a statistically significant impact on the percentage of
athletes who returned to play (w2 ¼ 6.05, df ¼ 3, P ¼ .110),
but there were significant differences in time to return to
play based on DVT location. Players with upper extremity
DVT had the fastest return to play (mean ± SD, 4.3 ± 2.7
months) compared with lower extremity DVT (5.9 ± 3.8
months), PE (10.8 ± 6.8 months), and DVT with PE (8.2 ±
2.6 months) (F ¼ 5.69, P ¼ .002). Seven players never
returned to play after the initial event (6 retired and 1 died
from a PE weeks after sustaining significant injuries in a
car accident), and 1 retired due to concerns after sustaining
a recurrent DVT/PE. One additional player has not yet
retired but has still not played since sustaining a DVT.
DISCUSSION
VTEs are estimated to occur at a rate of 1 to 2 events per
1000 people in the general population.2,19 Virchow’s triad of
venous stasis, endothelial injury, and a hypercoagulable
state is a long-recognized combination of risk factors for
DVT.19,34 Numerous conditions are associated with
increased risk of thrombosis, including both hereditary
clotting disorders and acquired conditions such as immobi-
lization, tissue trauma, pregnancy, smoking, advanced age,
obesity, oral contraceptive use, surgery, prolonged air
travel, and malignancy.2,10,19 Professional athletes are pre-
disposed to a number of these acquired conditions associ-
ated with an increased risk of thrombosis, including tissue
trauma from contact during play, hemoconcentration from
dehydration, circulatory stasis secondary to bradycardia
(high cardiopulmonary fitness), and long periods of immo-
bilization from either travel or injury.19,21 While obesity is
not a factor for most professional athletes, we found that 10
of the 12 NFL athletes who sustained a VTE were linemen,
with an average body mass index of 38.2 (range, 33.9-44.8).
Prior studies have shown an increased association between
obesity and VTE, suggesting that this relationship may
warrant closer investigation.12,26,41
Strenuous exercise itself may predispose some athletes
to hypercoagulability.15,19,20,30 Several studies have
explored the relationship between exercise and the blood
coagulation cascade, finding a blood level increase in pro-
thrombotic markers and factor VIII as well as simultaneous
activation of the fibrinolytic system and increased platelet
aggregation.15,19,20,30 Particularly for those athletes with
hereditary clotting disorders, studies have shown enhanced
clotting response to exercise in people with protein C defi-
ciency.47 De Caterina et al9 described 4 cases of DVT after
vigorous exercise in athletes who were carriers of protein C
deficiency. Parker et al37 specifically looked at the effect of
TABLE 4
Details of Venous Thromboembolic Events in NBA Playersa
Type of VTE Treatment Risk Factors Identified
Time Missed
From Play, mo
Year of
Event NBA Team
LE DVT Anticoagulation therapy (Coumadin 1 wk,
heparin daily injections after, aspirin
remainder of season)
Previous incidences (heart
episode [1996],
thrombophlebitis [1989])
0.43 2001 Houston Rockets
Anticoagulation therapy Previous DVT/PE CE 2016b Miami Heat
PE Anticoagulation therapy 3.00 2015 Brooklyn Nets
Surgical removal, anticoagulation therapy
(3 mo)
Postsurgical complication 9.37 2013 Cleveland Cavaliers
DVT and PE Anticoagulation therapy (Xarelto 3 mo),
followed by continual aspirin therapy
8.30 2015b Miami Heat
aCE, career ending; DVT, deep vein thrombosis; LE, lower extremity; NBA, National Basketball Association; PE, pulmonary embolism;
VTE, venous thromboembolism.
bAthlete with recurrent VTE.
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air travel on exercise-induced coagulatory and fibrinolytic
activation in Boston marathon runners and found that the
combination of air travel longer than 4 hours and endur-
ance running stimulated a prothrombotic state, inducing
an increase in procoagulatory factors relative to fibrinolytic
factors immediately after exercise.37 In our study, although
identifiable acquired major risk factors, including known
clotting disorder, family history of clotting disorder, preced-
ing injury or trauma, status postsurgery, and prior history
of clot, were noted in 22 cases of VTE, 33 had no identifiable
major risk factor, suggesting a more subtle predisposition
to coagulopathic events possibly related to the effects of
strenuous exercise or travel.
Frequent long-distance travel is a unique phenomenon
for professional athletes; games are played nationwide as
well as in other countries including Canada (NHL), China
(NBA), Europe (NFL), and Australia (MLB), and there are
plans by MLB to increase the number of international
games played.42 Professional athletes often travel immedi-
ately after games in the prothrombotic postexercise state,
as described by Parker et al.37 Studies have also shown an
increased risk of VTE with long-distance travel without
other acquired risk factors. Ferrari et al17 reported a
4-fold increased risk of VTE after 4 hours of travel (air-
plane, train, or car), and Philbrick et al38 showed an
increased risk after 6 hours of air travel. Interestingly, in
our study, we found no association between team geo-
graphic location (East Coast, West Coast, Midwest,
Canada) and risk of VTE (P ¼ .368), suggesting that geo-
graphic location of teams that potentially have to travel
farther for most play is not a major factor. However, most
team schedules are organized now so that away game
series are grouped by geographic location to reduce the
amount of time spent traveling for teams. Additionally,
high altitude is known to be a risk factor for developing
VTE with increased levels of hypoxia and hemoconcentra-
tion.13 This is particularly meaningful for those athletes
who train in places such as Denver, Colorado, where ath-
letic stadiums are all located at elevations over 5000 feet.
While our study is insufficiently powered to make any
conclusions, we noted that 2 MLB players from the Color-
ado Rockies sustained a VTE. Heightened awareness of
the signs and symptoms of VTE for athletes who compete
and train at elevation is important.
While we did not find a significant correlation with geo-
graphic location, the professional sport with the most VTEs
was the NHL (n¼ 22); of the 30 NHL teams, 7 are located in
Canada. It is possible that our numbers are too low to detect
a significant difference based on team location, but it
important to point out this finding because NHL players
likely spend more time traveling for games than do players
in other professional sports. Unique also to the NHL is that
athletes practice and play on an ice rink, where the average
temperature of the surface is below freezing. Numerous
studies have detected a seasonal relationship with the
pathogenesis of DVT,4,5,18,25 with DVTs occurring at a more
frequent rate in the winter months.8 While the association
between cold weather and DVT is not well understood, it is
postulated to be related to prothrombotic changes induced
by cold temperature35 or vasoconstriction18 or a link
between increased upper respiratory infections in winter
months and their relation to hypercoagulability.32,44
Upper extremity DVT/thoracic outlet syndrome, also
known as effort thrombosis of the subclavian vein or
Paget-Schroetter syndrome, was found to have unique char-
acteristics in our study compared with lower extremity DVT/
PE.33 Players who sustained an upper extremity DVT were
significantly younger (average age, 26 years) andmore likely
to return to play than those who sustained other forms of
VTE. All but 1 of the 19 upper extremity DVTs occurred in
NHL (n ¼ 7) and MLB athletes (n ¼ 11), with all MLB
athletes being pitchers. The repetitive overhead motion of
pitching is a previously described risk factor for developing
thoracic outlet syndrome, but not specifically DVT.11,24,33
The predilection for upper extremity VTE in MLB pitch-
ers may be due to biomechanical demands and altered blood
flow mechanics associated with the throwing motion of
pitchers. Bast et al1 demonstrated that peak blood flow in
the throwing arm of pitchers occurred at 40 pitches and
steadily declined as pitch count increased thereafter. Fur-
ther, the decrease in blood flow is dependent on the position
of the arm during throwing (abducted, horizontally
abducted, and externally rotated), with reduced blood flow
when the arm is in the throwing position compared with at
rest by the side.28 When compared with MLB positional
players, a significant difference in blood flow was noted
between the throwing arms of pitchers, but only for provoc-
ative position.28 Laudner et al29 measured a decrease in
blood flow during the provocative pitching position after 1
competitive season of pitching. As pitchers approach
fatigue in a simulated game, the biomechanical properties
of the pitching motion are only minimally altered, negating
the idea that shoulder and elbow torque increase as muscle
fatigue approaches.16 Additionally, thoracic outlet syn-
drome has rarely been reported in hockey players. Our
study suggests that this event may be more common in elite
hockey players than previously described. One could
hypothesize that this is associated with the repetitive
motion of stick handling or trauma due to frequent upper
body checks into the boards.
The literature has little information concerning acute
and long-term management of athletes who have sustained
a VTE or guidelines on return to play after VTE. Much of
the literature consists of case reports|| on diagnosis and
management. We found that the majority of VTEs in pro-
fessional athletes were treated with anticoagulants (oral or
injectable) (n ¼ 31, 56%), surgery (n ¼ 8, 15%), or a combi-
nation of the two (n ¼ 16, 29%). Of those players treated
with anticoagulants for a first-time DVT (n ¼ 47), the aver-
age length of treatment (of those with treatment data;
n ¼ 18) was 4.3 months. The 5 athletes who sustained a
recurrent VTE and were treated with anticoagulants were
placed on anticoagulation indefinitely after the recurrent
event. In our study, treatment of upper extremity DVT was
consistent with that reported in the literature; surgical clot
removal with or without first rib removal was performed in
all 19 athletes with upper extremity DVTs.33
||References 7, 11, 13, 14, 19, 22, 24, 27, 36, 39, 43, 45, 46, 48.
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The American College of Chest Physicians recommends a
minimum of 3 months of anticoagulation for the treatment
of DVT in a patient with modifiable risk factors.19 For a
patient without significant acquired risk factors, the Amer-
ican College of Chest Physicians recommends at least 3
months of anticoagulation and a subsequent risk-benefit
evaluation to determine the need for prolonged treat-
ment.19 While anticoagulation guidelines for DVT have
been established for the general population, these do not
necessarily apply to elite athletes because they have unique
requirements for their sports, including frequent travel,
vigorous training regimens, and risk of significant contact.
No evidence-based guidelines exist regarding when it is
safe for these athletes to return to play and whether it is
safe to play while receiving a form of anticoagulation.
Depenbrock10 attempted to create return-to-training
guidelines for athletes who had sustained a VTE, suggest-
ing that nonweightbearing activities can be resumed at 4
weeks after the event, nonimpact exercises such as cycling
at 5 weeks, and impact loading exercises such as running at
6 weeks. These guidelines were based on animal models of
the natural history of thrombosis, which show that by
weeks 4 to 6, dissolution of the clot and recanalization of
the vessel have occurred. Depenbrock’s10 guidelines recom-
mend return to contact sports only after completion of
anticoagulation therapy.
Berkowitz and Moll3 studied individualized, inter-
mittent anticoagulation management for athletes who sus-
tained a VTE, suggesting use of short-acting direct oral
anticoagulants (such as dabigatran) and personalized mea-
surements of the plasma half-life of the drug in the athlete’s
system to allow athletes to participate in contact sports
while receiving treatment for VTE. Compression stockings
are a noninvasive method that is frequently used to combat
circulatory stasis. Zaleski et al49 explored the effect of mar-
athon running and use of compression stockings on hemo-
stasis in a population of 20 runners; the investigators found
activation of hemostatic factors (both procoagulatory and
fibrinolytic) to be lower in the compression stocking group
than in controls. Zaleski et al49 concluded that compression
stockings do not adversely affect normal clotting system
activation with exercise but may lower overall activation,
which potentially could be beneficial for athletes traveling
long distances or with a known clotting history.
We looked at specific treatment regimens of some of the
players in our study population who returned to play after
sustaining a recurrent VTE; some of the interventions
included wearing compression stockings while traveling
and timed administration of anticoagulation based on prac-
tice and game schedules in 2 NHL players. One player was
reported to undergo monthly ultrasonography of the lower
extremities and abdomen for DVT screening. Overall, how-
ever, we found little consistency in treatment methods,
duration of treatment, and time lost from play among par-
ticipants with VTE in our study population.
Future considerations need to be explored for establish-
ing treatment guidelines and a timeline for safe return to
play after clotting events in the elite athlete. We found that
the average time of return to play was 6.7 months for all
forms of VTE and 4.3 months for upper extremity DVT. We
found no difference between sports regarding the number of
players affected and time to return to play. These are con-
siderable time periods for a professional athlete to be out of
competition, and they carry potentially significant mone-
tary and mental effects for the player as well as the team.
A better understanding of the pathogenesis of prothrombo-
tic factors in athletes and the effects of anticoagulation
treatment would allow for improvements in screening and
treatment of VTEs in athletes.
Improved treatment guidelines could significantly
reduce the time missed from competition; the current aver-
age time lost from play after a DVT is substantially greater
than the 3-month minimum treatment period recom-
mended by the American College of Chest Physicians.
Treatment that involves tailored dosing of anticoagulation,
based on pharmacokinetics of the drug in an individual
patient, might allow earlier return to play, which could be
particularly important for players with recurrent DVT or
known history of a hereditary clotting disorder. However,
further research is needed on this topic and the timing of
return to contact play, keeping in mind the risk-benefit
ratio for the athlete. Consideration should be given to
screening athletes for thrombogenic risk factors during
sports preparticipation physicals and preoperatively. Such
risk factors include prior venous thrombosis and family
history of hereditary clotting disorders; this is an important
consideration given that 27.2% (15/55) of VTEs in this study
were associated with either a personal or family history of
previous clots or a known clotting disorder.19 The role of
intermittent screening ultrasonography for those who have
had a DVT or who are at risk of DVT is not yet determined.
Finally, an improved database registry of VTE in athletes
would help researchers monitor the frequency of these
events and treatments used, in order to direct future
guidelines.
The results of this study must be viewed within the con-
text of the limitations. All of the data regarding incidence of
VTE, treatment, and return to play are drawn from media
reports found during internet searches and are not from
actual patient records. Only 1 article was identified
through the PubMed and SPORTDiscus search; that article
identified 3 NBA players with PE who were already
included from the Google search, and the remainder of ath-
letes included were from reports from the Google search.6
This may have resulted in a selection bias, such that our
study included high-profile professional athletes with
access to high levels of medical care and intense media
attention. Therefore, our study likely underestimated the
true incidence of VTE given that an unknown number of
athletes may have been missed.
Further, this study included only male athletes who were
at the peak of physical fitness and at the height of their
respective professional athletic leagues, potentially limit-
ing the scope of applicability. Female athletes were not
included in this analysis. Given women’s additional unique
risk factors for VTE, including oral contraceptive use and
pregnancy, inclusion of female athletes would be of interest
for future study. Additionally, full patient treatment data
and risk factor data were not available to us, since we exclu-
sively used publicly available data. For example, 8 patients
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were listed as being treated with surgery alone, but infor-
mation regarding anticoagulation treatment may not have
been included in the media report. Also, we found specific
data on length of anticoagulation treatment in only 18 of 55
athletes and data on specific risk factors in 22 of 55 ath-
letes.While it is possible that a number of these athletes did
not have identifiable risk factors, our data and results are
subject to the limitations of our search method, our limited
power to analyze risk factors, and the need for improved
database registries in American professional sports lea-
gues. Access to league injury databases would provide bet-
ter insight into the true incidence and clinical impact of
VTE in professional athletes. For return-to-play analysis,
if the VTE was season ending, the first game start date of
the next season was used as date of return, which may
have overestimated the actual time missed from the event.
Furthermore, any nonsignificant findings in this studymay
be a result of the small sample size, as VTE is a relatively
rare event. We believe that despite these unavoidable
shortcomings, this study adds value to the treatment of
athletes, as this is the first analysis of the impact of VTE
across all 4 major American professional sports. We hope
that this study provides a foundation for future research on
VTE management to help athletes stay healthy and get
back to their sport.
CONCLUSION
Overall, VTE is uncommon in NHL, NBA, MLB, and NFL
players; however, they are exposed to a number of acquired
risk factors that may predispose them to clotting, including
frequent travel, repetitive microtrauma, and hemoconcen-
tration from dehydration. The impact of vigorous exercise
on the coagulation cascade is not yet understood, and the
combined effect of exercise and hereditary clotting disorder
may compound these factors.19 While there is no consensus
on how to manage these events, this research showed that
the average time lost from play was 6.7 months and the
majority of American professional sports players were able
to return to play after a period of anticoagulation or sur-
gery. Those with an upper extremity DVT returned to play
faster than players with other types of VTE. Future study is
needed regarding appropriate treatment as well as screen-
ing and prevention guidelines for the elite athlete who sus-
tains a VTE.
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